MASARYKUV ONKOLOGICKY USTAV

Their core work

Masaryk Memorial Cancer Institute (MOU) is a specialized oncology research and treatment centre based in Brno, Czech Republic. They focus on cancer biology — spanning breast, colon, lung cancer, and melanoma — with particular strengths in biobanking, microbiome-cancer interactions, and precision medicine approaches. They also contribute expertise in environmental health science, studying how pollutants and toxic mixtures relate to cancer risk through toxicology and epidemiology. Their H2020 involvement has primarily been as a third-party contributor, providing clinical samples, biobank infrastructure, and domain-specific oncology knowledge to large European consortia.

What they specialise in

How they've shifted over time

MOU's early H2020 activity (2015–2017) centred on research infrastructure — biobanking operations and e-infrastructure through ADOPT BBMRI-ERIC and EGI-Engage. From 2019 onward, their focus shifted decisively toward translational cancer research and environmental health, joining ONCOBIOME (microbiome-cancer links, immunotherapy, precision medicine) and CETOCOEN Excellence (pollutant toxicology, environmental epidemiology). This progression from infrastructure support to active disease-focused research signals a maturing institution moving closer to clinical and translational impact.

MOU is deepening its role in translational oncology — particularly microbiome-driven diagnostics and immunotherapy — while expanding into environmental determinants of cancer, making them a strong partner for projects bridging environmental exposure and oncology outcomes.

How they like to work

MOU operates almost exclusively as a third-party contributor (3 of 4 projects), never as coordinator. This indicates they provide specialized clinical or analytical resources — likely patient cohorts, biobank samples, or domain expertise — to large consortia led by others. With 102 unique partners across 31 countries, they are well-connected despite their supporting role, suggesting they are a trusted specialist that consortium leaders actively seek out.

Despite modest direct funding, MOU has touched 102 unique consortium partners across 31 countries, reflecting the large-scale nature of the health and infrastructure projects they contribute to. Their network is broadly European with no obvious geographic concentration.

What sets them apart

MOU sits at a rare intersection: a dedicated oncology institute with both deep biobanking infrastructure and active research into how environmental pollutants drive cancer. This combination — clinical cancer data, biospecimen collections, and environmental health expertise — is uncommon among European cancer centres. For consortium builders, MOU offers access to a specialized oncology biobank in Central Europe, a region often underrepresented in large health projects, which can be valuable for geographic diversity requirements.

Highlights from their portfolio

• ONCOBIOME
  Large-scale study (2019–2025) investigating gut microbiome signatures across four major cancer types, linking microbiome research to immunotherapy and precision medicine.
• CETOCOEN Excellence
  Long-running Widening project (2020–2027) bridging environmental toxicology with health outcomes — unusual for a cancer institute, signalling interdisciplinary ambition.
• ADOPT BBMRI-ERIC
  MOU's only direct participation (not third party), implementing the pan-European biobank gateway — their foundational infrastructure contribution.